

## Organisation

University Children's Hospital  
Department of Pediatric Surgery and Urology  
Department of Pediatric Hematology / Oncology

Hoppe-Seyler-Str. 3  
D-72076 Tuebingen  
Germany

## Scientific Committee

Prof. Dr. med. Jörg Fuchs

Prof. Dr. med. Peter Lang

Prof. Dr. med. Steven Warmann  
steven.warmann@med.uni-tuebingen.de

PD Dr. Evi Schmid  
evi.schmid@med.uni-tuebingen.de

Dr. Andreas Schmidt  
andreas.schmidt@med.uni-tuebingen.de

## Congress Management

b4c & solutions GmbH  
Breslauer Straße 40

82194 Gröbenzell

Diana Heidenberger  
+49 8142 4219481  
+49 8142 4219482

info@b4c-solutions.de


www.b4c-solutions.de

## Impressum

University Children's Hospital Tübingen, Germany  
Department of Pediatric Surgery and Urology  
Department of Pediatric Hematology / Oncology  
© 2022 Universitätsklinikum Tübingen  
www.medizin.uni-tuebingen.de

## Children's Hospital

Department of Pediatric Surgery and Pediatric Urology  
Department of Pediatric Hematology/Oncology



# 8<sup>th</sup> International Tübingen-Symposium on Pediatric Solid Tumors

Neuroblastoma  
December 9 – 10, 2022  
Tübingen, Germany



[www.neuroblastoma-tuebingen2022.com](http://www.neuroblastoma-tuebingen2022.com)



Universitätsklinikum  
Tübingen

## Provisional Program

### Friday, December 9, 2022

08.30 – 08.45 Welcome

*Jörg Fuchs and Peter Lang*

08.45 – 10.00 Session 1: New aspects of risk stratification

New aspects and clinical relevance of the COG neuroblastoma risk stratification

*Meredith Irwin (Toronto)*

New risk stratification of neuroblastoma – common strategies between SIOPEN and GPOH

*Prof. Angelika Eggert (Berlin)*

How relevant is pathology for diagnosis and the decision making process in neuroblastoma risk stratification

*Prof. Christian Vokuhl (Bonn)*

Molecular genetics of neuroblastoma and its clinical implications

*Matthias Fischer (Köln)*

10.00 – 10.20 Coffee Break

10.20 – 11.50 Session 2: Radiology and new aspects of diagnostic workup

Imaging in neuroblastoma: Recommendations of the SIOPEN Radiological Committee

*Irmina Sevic (Sarajevo)*

18F-meta-fluorobenzylguanidine (18F-mFBG) in neuroblastoma: Pros and cons

*Bart de Keizer (Utrecht)*

Combined metabolic and functional tumor volumes on PET/MRI in neuroblastoma

*Maryanna Chaika (Tübingen)*

Imaging of gross residual disease after surgery in neuroblastoma: The COG experience

*Stephan Voss (Boston)*

Early postoperative MRI after gross total resection: Tübingen experience and first results of a multicenter study

*Sebastian Gassenmaier (Tübingen)*

11.50 – 12.50 Lunch Break

12.50 – 13.50 Session 3: Radiation Therapy

The evolving role of radiotherapy in neuroblastoma

*Beate Timmermann (Essen)*

The evolution of radiotherapy utilization in high-risk neuroblastoma: Recent missteps and future directions

*Dr. John Lucas (Memphis)*

Results and complications of radiotherapy in neuroblastoma

*Mark Gaze (London)*

13.50 – 14.15 Coffee Break

14.15 – 15.45 Session 4: Immunotherapy / Car-T-cells

Development of an anti-GD2/B7-H3 bispecific antibody to improve tumor targeting, reduce toxicity and improve efficacy for neuroblastoma

*Paul Sondel (Madison)*

Targeting T cells and radioisotopes using bispecific antibodies

*Nai-Kong Cheung (New York)*

Haploidentical stem cell transplantation followed by anti-GD2 therapy in relapsed neuroblastoma

*Peter Lang (Tübingen)*

Long-term infusion

*Holger Lode (Greifswald)*

Dissecting the immunobiology of GD2

*Robbi Majzner (Stanford)*

15.45 – 16.05 Coffee Break

16.05 – 17.05 Session 5: Free talks

18.30 Congress Dinner

### Saturday, December 10, 2022

09.00 – 09.15 Key Note Lecture:

History of neuroblastoma surgery

*Mike LaQuaglia, (New York)*

09.15 – 11.05 Session 6: Surgery

Relevance of imaging and pre-treatment of high risk neuroblastoma surgery

*Jörg Fuchs (Tübingen)*

Minimally invasive surgery for neuroblastoma: What's new?

*Sabine Sarnacki (Paris)*

Surgery of ganglioneuroma

*Sabine Irtan (Paris)*

Complications associated with neuroblastoma surgery

*Andrew Davidoff (Memphis)*

Challenges in neuroblastoma surgery

*Chan Hon Chui (Singapur)*

The International Surgical Report Form and the complexity index for neuroblastoma

*Patrizia Dall'Igna (Bari)*

11.05 – 11.25 Coffee Break

11.25 – 13.15 Session 7: Clinical Trials

GPOH results of neuroblastoma studies

*Thorsten Simon (Köln)*

Neuroblastoma trials Asia

*Godfrey Chan (Singapur)*

High-risk neuroblastoma from the COG perspective

*Rochelle Bagatell (Philadelphia)*

Low- and intermediate-risk neuroblastoma

*Maja Popovic Beck (Lausanne)*

Therapeutic strategies for high-risk neuroblastoma in Europe

*Ruth Ladenstein (Wien)*

Management of infant neuroblastoma

*Barbara Hero (Köln)*

13.15 – 14.15 Lunch Break

14.15 – 15.45 Session 8: Basic Research

Evolving approaches to IL2-based therapeutics.

*Steven Gilis (Boston)*

Downstream signalling pathways and ALK inhibitor resistance in neuroblastoma

*Johannes Schulte (Berlin)*

Cellular origin and genomic evolution of childhood neuroblastoma

*Dr. Frank Westermann (Heidelberg)*

Free talks

15.45 Closing Remarks

*J. Fuchs and P. Lang*